Regeneron Pharmaceuticals Investor Presentation — January 2020

Document content

LEONARD S. SCHLEIFER MD, P hD

P R E S I D E N T & C E O

GEORGE D. YANCOPOULOS MD, P hD

P R E S I D E N T & C S OJP MORGAN 2020

2NOTE REGARDING FORWARD -LOOKING STATEMENTS

AND NON -GAAP FINANCIAL MEASURES

This presentation includes forward -looking statements thatinvolve risks anduncertainties relating tofuture events andthefuture performance ofRegeneron Pharmaceuticals, Inc.(“Regeneron” orthe“Company”), andactual events orresults may differ

materially from these forward -looking statements .Words such as���anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations ofsuch words, andsimilar expressions areintended toidentify such forward -looking statements, although notall

forward -looking statements contain these identifying words .These statements concern, andthese risks anduncertainties include, among others, thenature, timing, andpossible success andtherapeutic applications ofproducts marketed byRegeneron

and/or itscollaborators (collectively, “Regeneron’s Products”) andRegeneron’s product candidates andresearch andclinical programs now underway orplanned, including without limitation EYLEA® (aflibercept) Injection, Dupixent® (dupilumab ),Libtayo ®

(cemiplimab), Praluent ®(alirocumab), Kevzara ®(sarilumab ),fasinumab ,evinacumab ,garetosmab ,pozelimab ,Regeneron’s immuno -oncology programs (including itscostimulatory bispecific portfolio), Regeneron’s earlier -stage product candidates, andthe

useofhuman genetics inRegeneron’s research programs ;theextent towhich theresults from Regeneron’s research programs orpreclinical testing may lead toadvancement ofproduct candidates toclinical trials ortherapeutic applications ;unforeseen

safety issues resulting from theadministration ofRegeneron’s Products andproduct candidates inpatients, including serious complications orside effects inconnection with theuseofRegeneron’s product candidates inclinical trials ;thelikelihood and

timing ofpossible regulatory approval andcommercial launch ofRegeneron’s late-stage product candidates andnew indications forRegeneron’s Products including without limitation EYLEA, Dupixent, Libtayo ,Praluent ,Kevzara ,fasinumab ,evinacumab ,

REGN -EB3,garetosmab ,pozelimab ,andREGN 1979 ;thelikelihood andtiming ofachieving anyoftheanticipated milestones described inthispresentation ;theextent towhich theresults from theresearch anddevelopment programs conducted by

Regeneron oritscollaborators may bereplicated inother studies andlead totherapeutic applications ;ongoing regulatory obligations andoversight impacting Regeneron’s Products (such asEYLEA, Dupixent, Libtayo ,Praluent ,andKevzara ),research and

clinical programs, andbusiness, including those relating topatient privacy ;determinations byregulatory andadministrative governmental authorities which may delay orrestrict Regeneron’s ability tocontinue todevelop orcommercialize Regeneron’s